#ESC22: ‘Anx­ious for more ev­i­dence’: As­traZeneca touts DE­LIV­ER da­ta in bid to ex­pand Farx­i­ga’s heart fail­ure la­bel 

BARCELONA — Three and a half months af­ter teas­ing a topline win for its heart fail­ure and type 2 di­a­betes med Farx­i­ga, As­traZeneca laid out the de­tails of the drug’s per­for­mance in an­oth­er heart fail­ure pa­tient pop­u­la­tion to a crowd at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress.

The UK Big Phar­ma said its drug led to an 18% re­duc­tion in a com­pos­ite end­point com­pris­ing car­dio­vas­cu­lar death or wors­en­ing heart fail­ure, good for a p-val­ue less than 0.001, over a me­di­an fol­low-up of 2.3 years. Bro­ken down, the rel­a­tive risk re­duc­tion was: 21% for wors­en­ing HF, 23% for HF hos­pi­tal­iza­tions and 12% for CV death.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER